The Tumor Pathology of Genetically Engineered Mice: A New Approach to Molecular Pathology

The Mouse in Biomedical Research

Volumn 2, Issue , 2007, Pages 581-622

  Cardiff, Robert D ^a   Munn, Robert J ^a   Galvez, Jose J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77649199829     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012369454-6/50052-2     Document Type: Chapter

References (211)

1. Abate-Shen C., Banach-Petrosky W.A., Sun X., Economides K.D., Desai N., Gregg J.P., et al. Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res. 2003, 63(14):3886-3890.
2. Al-Hajj M., Clarke M.F. Self-renewal and solid tumor stem cells. Oncogene 2004, 23(43):7274-7282.
3. Ali S.H., DeCaprio J.A. Cellular transformation by SV40 large T antigen: interaction with host proteins. Semin. Cancer Biol 2001, 11(1):15-23.
4. Anbazhagan R., Tihan T., Bornman D.M., Johnston J.C., Saltz J.H., Weigering A., et al. Classification of small cell lung cancer and pul-monary carcinoid by gene expression profiles. Cancer Res. 1999, 59(20):5119-5122.
5. Andrechek E.R., Hardy W.R., Siegel P.M., Rudnicki M.A., Cardiff R.D., Muller W.J. Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. Proc. Natl. Acad. Sci. USA 2000, 97:3444-3449. 7.
6. Andrechek E.R., Laing M.A., Girgis-Gabardo A.A., Siegel P.M, Cardiff R.D., Muller W.J. Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. Cancer Res. 2003, 63(16):4920-4926.
7. Andrechek E.R., Muller W.J. Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2000, 2(3):211-216.
8. Andres A.C., Schonenberger C.A., Groner B., Hennighausen L., LeMeur M., Gerlinger P. Ha-ras oncogene expression directed by a milk protein gene promoter: tissue specificity hormonal regulation and tumor induction in transgenic mice. Proc Natl. Acad Sci USA 1987, 84(5):1299-1303.
9. Apolant H. Die epithelialen Geschwulste der Maus. Arbeiten aus dem Koniglichen Institut fur Experimentelle Therapie zu Frankfurt 2006, 7-62.
10. Arbeit J.M. Mouse models of cervical cancer. Comp. Med. 2003, 53(3):256-258.
11. Ashley R.L., Cardiff R.D., Mitchell D.J., Faulkin L.J., Lund J.K. Development and characterization of mouse hyperplastic mammary outgrowth lines from BALB/cfC3H hyperplastic alveolar nodules. Cancer Res. 1980, 40(11):4232-4242.
12. Balmain A., Nagase H. Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet. 1998, 14(4):139-144.
13. Bannasch P., Enzmann H., Klimek E, Weber E., Zerban H. Significance of sequential cellular changes inside and outside foci of altered hepatocytes during hepatocarcinogenesis. Toxicol. Pathol. 1989, 17:617-628. (4 Pt. 1), discussion 629.
14. Bargmann C.I., Hung M.C., Weinberg R.A. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 1986, 319(6050):226-230.
15. Barthold S.W. quot;Muromics quot;: genomics from the perspective of the laboratory mouse. Comp. Med. 2002, 52(3):206-223.
16. Berg D.J., Davidson N., Kuhn R., Muller W., Menon S., Holland G., et al. Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4 (+) THl-like responses. J. Clin. Invest. 1996, 98(4):1010-1020.
17. Berman J.J. Tumor classification: molecular analysis meets Aristotle. BMC Cancer 2004, 4(1):10.
18. Bierie B., Nozawa M., Renou J.P., Shillingford J.M., Morgan R, Oka T., et al. Activation of beta-catenin in prostate epithelium induces hyper-plasias and squamous transdifferentiation. Oncogene 2003, 22(25):3875-3887.
19. Blair P.B. The mammary tumor virus (MTV). Curr. Top. Microbiol Immunol. 1968, 45:1-69.
20. Boivin G.P., Washington K., Yang K., Ward J.M., Pretlow T.P., Russell R., et al. Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003, 124(3):762-777.
21. Borowsky A., Galvez J., Munn R., Cardiff R. Comparative pathology of mouse models of human cancers. Comp. Med. 2003, 53(3):248-249.
22. Borowsky A.D., Munn R.J., Galvez J.J., Cardiff R.D., Ward J.M., Morse H.C., et al. Mouse models of human cancers (part 3). Comp. Med. 2004, 54(3):258-270.
23. Bouchard L., Lamarre L., Tremblay P.J., Jolicoeur P. Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene. Cell 1989, 57(6):931-936.
24. Brinster R.L., Chen H.Y., Messing A., van Dyke T., Levine A.J., Palmiter R.D. Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984, 37(2):367-379.
25. Capen C.C., Karbe E., Deschl U., George C., Germann P.-G., Gopinath C, et al. Endocrine System. Pituitary Gland. International classifica- tion of rodent tumors. The mouse 2001, 270-283. Springer-Verlag, Berlin. U. Mohr (Ed.).
26. Cardiff R.D. Protoneoplasia: the molecular biology of murine mammary hyperplasia. Adv. Cancer Res. 1984, 42:167-190.
27. Cardiff R.D. Cellular and molecular aspects of neoplastic progression in the mammary gland. Eur. J. Cancer Clin. Oncol. 1988, 24(1):15-20.
28. Cardiff R.D. The biology of mammary transgenes: five rules. J. Mammary Gland. Biol. Neoplasia 1996, 1(1):61-73.
29. Cardiff R.D. Validity of mouse mammary tumour models for human breast cancer: comparative pathology. Microsc. Res. Tech. 2001, 52(2):224-230.
30. Cardiff R.D. Mouse models of human breast cancer. Comp. Med. 2003, 53(3):250-253.
31. Cardiff R.D. Pathology of Mouse Models of Cancer. Mouse models of human cancer 2004, 15-30. Wiley-Liss, Hoboken NJ. E.C. Holland (Ed.).
32. Cardiff R.D., Aguilar-Cordova E. Proto-neoplasia revisited: the molecular biology of mouse mammary hyperplasia. Anticancer Res. 1988, 8(5A):925-933.
33. Cardiff R.D., Aguilar-Cordova E. Protoneoplasia revisited: The molecular biology of mouse mammary hyperplasia. (Review). Anticancer Research 1988, 8(5):925-933.
34. Cardiff R.D., Anver M.R., Gusterson B.A., Hennighausen L., Jensen R.A., Merino M.J., et al. The mammary pathology of genetically engi-neered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000, 19(8):968-988.
35. Cardiff R. D. Bern H. A. Faulkin L. J. Daniel C. W Smith G. H. Young L. J. et al. Contributions of mouse biology to breast cancer research. Comp. Med. 52(1) 12-31.
36. Cardiff R.D., Gumerlock P.H., Soong M.M., Dandekar S., Barry P.A., Young L.J., et al. c-H-ras-1 expression in 7 12-dimethyl benzan-thracene-induced Balb/c mouse mammary hyperplasias and their tumors. Oncogene 1988, 3(2):205-213.
37. Cardiff R.D., Leder A., Kuo A., Pattengale P.K., Leder P. Multiple tumor types appear in a transgenic mouse with the ras oncogene. Am. J. Pathol. 1993, 142(4):1199-1207.
38. Cardiff R.D., Moghanaki D., Jensen R.A. Genetically engineered mouse models of mammary intraepithelial neoplasia. J. Mammary Gland. Biol. Neoplasia 2000, 5(4):421-437.
39. Cardiff R.D., Muller W.J. Transgenic mouse models of mam-mary tumorigenesis. Cancer Surv. 1993, 16:97-113.
40. Cardiff R.D., Munn R.J. Comparative pathology of mammary tumorigenesis in transgenic mice. Cancer Lett. 1995, 90(1):13-19.
41. Cardiff R.D., Ornitz D., Lee F., Moreadith R., Sinn E., Muller W, et al. Mammary morphogenesis and oncogenes. In Breast cancer. Progress in biology clinical management and prevention 1992, 41-55.
42. Cardiff R.D., Rosner A., Hogarth M.A., Galvez J.J., Borowsky A.D., Gregg J.P. Validation: the new challenge for pathology. Toxicol. Pathol. 2004, 32(Suppl. 1):31-39.
43. Cardiff R.D., Sinn E., Muller W., Leder P. Transgenic oncogene mice. Tumor phenotype predicts genotype. Am. J. Pathol. 1991, 139(3):495-501.
44. Cardiff R.D., Wagner U., Henninghausen L. Mammary cancer in humans and mice: a tutorial for comparative pathology. The CD-ROM. J. Mammary Gland. Biol. Neoplasia 2000, 5(2):243-244.
45. Cardiff R.D., Wagner U., Henninghausen L. Mammary cancer in humans and mice: a tutorial for comparative pathology. Vet. Pathol. 2001, 38(4):357-358.
46. Cardiff R.D., Wellings S.R. The comparative pathology of human and mouse mammary glands. J. Mammary Gland. Biol. Neoplasia 1999, 4(1):105-122.
47. Cardiff R.D., Wellings S.R., Faulkin L.J. Biology of breast preneoplasia. Cancer 1977, 39(6 Suppl.):2734-2746.
48. Chatterjee G., Rosner A., Han Y, Zelazny E.T., Li B., Cardiff R.D., et al. Acceleration of mouse mammary tumor virus-induced murine mam- mary tumorigenesis by a p53 172H transgene: influence of FVB background on tumor latency and identification of novel sites of proviral insertion. Am. J. Pathol. 2002, 161(6):2241-2253.
49. Cheung A.T.W., Young L.J.T., Chen P.C.Y, Chao C.Y, Ndoye A., Barry P.A., et al. Microcirculation and metastasis in a new mouse mam-mary tumor model system. Int. J. Oncology 1997, 11:69-77.
50. Cramer S.F. Diagnostic accuracy of second-opinion diagnoses based on still images. Hum. Pathol. 2004, 35(7):904.
51. Dankort D., Maslikowski B., Warner N., Kanno N., Kim H., Wang Z., et al. Grb2 and Shc adapter proteins play distinct roles in Neu (ErbB-2) -induced mammary tumorigenesis: implications for human breast cancer. Mol. Cell. Biol. 2001, 21(5):1540-1551.
52. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E., et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat. Med. 2001, 7(2):235-239.
53. Deckard-Janatpour K., Muller W.J., Chodosh L.A., Gardner H.P., Marquis S.T., Coffey R.J., et al. Differential expression of the neu transgene in murine mammary tissues. Int. J. Oncology 1997, 11:235-244.
54. Desai K.V., Xiao N., Wang W, Gangi L., Greene J., Powell J.L, et al. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc. Natl. Acad. Sci. USA 2002, 99:6967-6972. 10.
55. Di Carlo E., Diodoro M.G., Boggio K., Modesti A., Modesti M., Nanni P., et al. Analysis of mammary carcinoma onset and progression in HER-2/neu oncogene transgenic mice reveals a lobular origin. Lab. Invest. 1999, 79(10):1261-1269.
56. DiGiovanna M.P., Lerman M.A., Coffey R.J., Muller W.J., Cardiff R.D., Stern D.F. Active signaling by Neu in transgenic mice. Oncogene 1998, 17(14):1877-1884.
57. Donehower L.A., Harvey M., Slagle B.L., McArthur M.J., Montgomery C.A., Butel J.S., et al. Mice deficient for p53are develop-mentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221. 6366.
58. Donjacour A.A., Thomson A.A., Cunha G.R. Enlargement of the ampullary gland and seminal vesicle but not the prostate in int-2/Fgf-3 transgenic mice. Differentiation 1998, 62(5):227-237.
59. Dragani T.A. Ten years of mouse cancer modifier loci: human relevance. Cancer Res. 2003, 63(12):3011-3018.
60. Dunn T.B. Morphology of mammary tumors in mice. The phys- iopathology of cancer 1953, 123-148. Cassel, London. F. Homburger (Ed.).
61. Ellwood-Yen K., Graeber T.G., Wongvipat J., Iruela-Arispe M.L., Zhang J., Matusik R., et al. Myc-driven murine prostate cancer shares molec-ular features with human prostate tumors. Cancer Cell 2003, 4(3):223-238.
62. Evangelou A.I., Winter S.F., Huss W.J., Bok R.A., Greenberg N.M. Steroid hormones polypeptide growth factors hormone refractory prostate cancer and the neuroendocrine phenotype. J. Cell. Biochem. 2004, 91(4):671-683.
63. Ewart-Toland A., Briassouli P., de Koning J.P., Mao J.H., Yuan J., Chan F., et al. Identification of Stk6/STK15 as a candidate low-penetrance tumor-susceptibility gene in mouse and human. Nat. Genet. 2003, 34(4):403-412.
64. Fargiano A.A., Desai K.V., Green J.E. Interrogating mouse mammary cancer models: insights from gene expression profiling. J. Mammary Gland. Biol. Neoplasia 2003, 8(3):321-334.
65. Experimental biology and oncology 1982, Vol. 4. Academic Press, San Diego. H.L. Foster, J.D. Small, J.G. Fox (Eds.).
66. Foulds L. Experimental study of the course and regulation of tumour growth. Ann. R. Coll. Surg. Engl. 1951, 9(2):93-101.
67. Foulds L. The natural history of cancer. J. Chronic Dis. 1958, 8(1):2-37.
68. Franke T.F., Hornik C.P, Segev L., Shostak G.A., Sugimoto C. PI3K/Akt and apoptosis: size matters. Oncogene 2003, 22(56):8983-8998.
69. Freeman D.J., Li A.G., Wei G., Li H.H., Kertesz N., Lesche R., et al. PTEN tumor suppressor regulates p53protein levels and activity through phosphatase. Cancer Cell 2003, 3(2):117-130.
70. Frith C.H., Ward J.M. Color atlas of neoplastic and non-neoplastic lesions in aging mice 1988, Elsevier, Amsterdam; New York.
71. Furth P.A. SV40 rodent tumour models as paradigms of human disease: transgenic mouse models. Dev. Biol. Stand. 1998, 94:281-287.
72. Gabrielson E., Berg K., Anbazhagan R. Functional genomics gene arrays and the future of pathology. Mod. Pathol. 2001, 14(12):1294-1299.
73. Galvez J.J., Cardiff R.D., Munn R.J., Borowsky A.D., Boivin G.P., Groden J., et al. Mouse models of human cancers (Part 2). Comp. Med. 2004, 54(1):13-28.
74. Garabedian E.M., Humphrey P.A., Gordon J.I. A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells. Proc. Natl. Acad. Sci. USA 1998, 95:15382-15387. 26.
75. Gardner M.B., Arnstein P., Johnson E., Rongey R.W., Charman H.P., Huebner R.J. Feline sarcoma virus tumor induction in cats and dogs. J. Am. Vet. Med. Assoc. 1971, 158(6):1046. Suppl. 2.
76. Gardner M.B., Henderson B.E., Rongey R.W, Estes J.D., Huebner R.J. Spontaneous tumors of aging wild house mice. Incidence pathol-ogy and C-type virus expression. J. Natl. Cancer Inst. 1973, 50(3):719-734.
77. Gardner M.B., Malone R.W., Morris D.W, Young L.J., Strange R., Cardiff R.D., et al. Mammary tumors in feral mice lacking MuMTV DNA. J. Exp Pathol. 1985, 2(2):93-98.
78. Gardner M.B., Rongey R.W., Arnstein P., Estes J.D., Sarma P., Huebner R.J., et al. Experimental transmission of feline fibrosarcoma to cats and dogs. Nature 1970, 226(5248):807-809.
79. Gingrich J.R., Barrios R.J., Foster B.A., Greenberg N.M. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis. 1999, 2(2):70-75.
80. Gingrich J.R., Barrios R.J., Morton R.A., Boyce B.F., DeMayo F.J., Finegold M.J., et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 1996, 56(18):4096-4102.
81. Golub T.R., Slonim D.K., Tamayo P., Huard C., Gaasenbeek M., Mesirov J.P., et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286(5439):531-537.
82. Gottlieb K.A., Villarreal L.P. Natural biology of polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 2001, 65(2):288-318. second and third pages table of contents.
83. Green J.E., Cardiff R., Hennighausen L., Wakefield L., Wagner U., Lee E., et al. Validation of transgenic mammary cancer models: goals of the NCI Mouse Models of Human Cancer Consortium and the mammary cancer CD-ROM. Transgenic Res. 2002, 11(6):635-636.
84. Green J. E. Shibata M. A. Yoshidome K. Liu M. L. Jorcyk C. Anver M. R. et al. The C3(l)/SV40 T-antigen transgenic mouse model of mammary cancer: ductal epithelial cell targeting with multistage progression to carcinoma. Oncogene 19(8) 1020-1027.
85. Greenberg N.M., DeMayo F, Finegold M.J., Medina D., Tilley W.D., Aspinall J.O., et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 1995, 92:3439-3443. 8.
86. Gum J.R., Hicks J.W, Crawley S.C., Yang S.C., Borowsky A.D., Dahl C.M., et al. Mice expressing SV40 T antigen directed by the intestinal trefoil factor promoter develop tumors resembling human small cell carcinoma of the colon. Mol. Cancer Res. 2004, 2(9):504-513.
87. Gunther E.J., Belka G.K., Wertheim G.B., Wang J., Hartman J.L., Boxer R.B., et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. Faseb. J. 2002, 16(3):283-292.
88. Gunther E.J., Moody S.E., Belka G.K., Hahn K.T., Innocent N., Dugan K.D., et al. Impact of p53loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 2003, 17(4):488-501.
89. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell. Biol 1992, 12(3):954-961.
90. Guy C.T., Cardiff R.D., Muller W.J. Activated neu induces rapid tumor progression. J. Biol. Chem. 1996, 271(13):7673-7678.
91. Guy C.T., Muthuswamy S.K., Cardiff R.D., Soriano P., Muller W.J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 1994, 8(1):23-32.
92. Guy C.T., Webster M.A., Schaller M., Parsons T.J., Cardiff R.D., Muller W.J. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 1992, 89:10578-10582. 22.
93. Haaland M. Spontaneous tumors in mice. Fourth Sci. Report Imperial Cancer Res. Fund 1911, 4:1-113.
94. Hager J.H., Hanahan D. Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcino-genesis. Ann. N. Y. Acad. Sci. 1999, 887:150-163.
95. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100(1):57-70.
96. Harrington L. Does the reservoir for self-renewal stem from the ends?. Oncogene 2004, 23(43):7283-7289.
97. Hingorani S.R., Petricoin E.F, Maitra A., Rajapakse V., King C., Jacobetz M.A., et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 2003, 4(6):437-450.
98. Hingorani S.R., Tuveson D.A. In search of an early warning system for pancreatic cancer. Cancer Biol. Ther. 2003, 2(1):84-86.
99. Mouse models of human cancer 2004, 15-30. Wiley-Liss, Hoboken NJ. E.C. Holland (Ed.).
100. Huseby R.A., Soares M.J., Talamantes F Ectopic pituitary grafts in mice: hormone levels effects on fertility and the development of adeno-myosis uteri prolactinomas and mammary carcinomas. Endocrinology 1985, 116(4):1440-1448.
101. Hutchinson J., Jin J., Cardiff R.D., Woodgett J.R., Muller W.J. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 2001, 21(6):2203-2212.
102. Jain K.K. Applications of biochips: from diagnostics to personalized medicine. Curr. Opin. Drug Discov. Devel. 2004, 7(3):285-289.
103. Janssen K.P., el-Marjou F., Pinto D., Sastre X., Rouillard D., Fouquet C., et al. Targeted expression of oncogenic K-ras in intestinal epithelium causes spontaneous tumorigenesis in mice. Gastroenterology 2002, 123(2):492-504.
104. Kasper S., Sheppard P.C., Yan Y., Pettigrew N., Borowsky A.D., Prins G.S., et al. Development progression and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab. Invest. 1998, 78(3):319-333.
105. Kawakami T.G., Buckley P., Huff S., McKain D., Fielding H. A comparative study in vitro of a simian virus isolated from spontaneous woolly monkey fibrosarcoma and of a known feline fibrosarcoma virus. Bibl. Haematol 1973, 39:236-243.
106. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., Desai N., Wang Y., Hayward S.W., et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 2002, 62(11):2999-3004.
107. Kim M.J., Cardiff R.D., Desai N., Banach-Petrosky W.A., Parsons R., Shen M.M., et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 2002, 19:19.
108. Kirsten W.H., Mayer L.A. Malignant lymphomas of extrathymic origin induced in rats by murine erythroblastosis virus. J. Natl. Cancer Inst. 1969, 43(3):735-746.
109. Kishimoto H., Hamada K., Saunders M., Backman S., Sasaki T., Nakano T., et al. Physiological functions of Pten in mouse tissues. Cell Struct. Funct. 2003, 28(1):11-21.
110. Kogan S. C. Ward J. M. Anver M. R. Berman J. J. Brayton C. Cardiff R. D. et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood 100(1) 238-245.
111. Kovalchuk A.L., Qi C.F, Torrey T.A., Taddesse-Heath L., Feigenbaum L., Park S.S., et al. Burkitt lymphoma in the mouse. J. Exp. Med. 2000, 192(8):1183-1190.
112. Kullberg M.C., Ward J.M., Gorelick P.L., Caspar P., Hieny S., Cheever A., et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-lO) -deficient mice through an IL-12-and gamma interferon-dependent mechanism. Infect. Immun. 1998, 66(11):5157-5166.
113. Kumar R., Sukumar S., Barbacid M. Activation of ras oncogenes preceding the onset of neoplasia. Science 1990, 248(4959):1101-1104.
114. Laboratory R.B.J.M. Genes mice and men; a quarter-century of progress 1953, Bar Harbor, Bar Harbor.
115. Landesman-Bollag E., Romieu-Mourez R., Song D.H., Sonenshein G.E., Cardiff R.D., Seldin D.C. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001, 20(25):3247-3257.
116. Le Voyer T., Lu Z., Babb J., Lifsted T., Williams M., Hunter K. An epistatic interaction controls the latency of a transgene-induced mammary tumor. Mamm. Genome 2000, 11(10):883-889.
117. Leder A., Kuo A., Cardiff R.D., Sinn E., Leder P. v-Ha-ras trans-gene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc. Natl. Acad. Sci. USA 1990, 87:9178-9182. 23.
118. Lee F.S., Lane T.F., Kuo A., Shackleford G.M., Leder P. Insertional mutagenesis identifies a member of the Wnt gene family as a candidate oncogene in the mammary epithelium of int-2/Fgf-3 transgenic mice. Proc. Natl. Acad. Sci. USA 1995, 92:2268-2272. 6.
119. Li B., Rosen J.M., McMenamin-Balano J., Muller W.J., Perkins A.S. neu/ERBB2 cooperates with p53-172H during mammary tumorigene-sis in transgenic mice. Mol. Cell. Biol. 1997, 17(6):3155-3163.
120. Li Y, Welm B., Podsypanina K., Huang S., Chamorro M., Zhang X., et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. USA 2003, 100:15853-15858. 26.
121. Lin E.Y, Pollard J.W. Macrophages: modulators of breast cancer progression. Novartis Found. Symp. 2004, 256:158-168. discussion.
122. Lin E.Y, Pollard J.W. Macrophages: modulators of breast cancer progression. Novartis Found. Symp. 2004, 256:168-172.
123. Lin E.Y, Pollard J.W. Macrophages: modulators of breast cancer progression. Novartis Found. Symp. 2004, 256:259-269.
124. Lin L., Festing M.F., Devereux T.R., Crist K.A., Christiansen S.C., Wang Y, et al. Additional evidence that the K-ras protooncogene is a can-didate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp. Lung Res. 1998, 24(4):481-497.
125. Lin S.C., Lee K.F, Nikitin A.Y, Hilsenbeck S.G., Cardiff R.D., Li A., et al. Somatic mutation of p53leads to estrogen receptor alpha-positive and-negative mouse mammary tumors with high frequency of metastasis. Cancer Res. 2004, 64(10):3525-3532.
126. Linnoila R.I., Sahu A., Miki M., Ball D.W, DeMayo F.J. Morphometric analysis of CC10-hASHl transgenic mouse lung: a model for bronchiolization of alveoli and neuroendocrine carcinoma. Exp. Lung Res. 2000, 26(8):595-615.
127. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432(7015):307-315.
128. MacArthur C.A., Shankar D.B., Shackleford G.M. Fgf-8 activated by proviral insertion cooperates with the Wnt-1 transgene in murine mammary tumorigenesis. J. Virol. 1995, 69(4):2501-2507.
129. Maglione J.E., McGoldrick E.T., Young L.J., Namba R., Gregg J.P., Liu L., et al. Polyomavirus middle T-induced mammary intraepithelial neo-plasia outgrowths: single origin divergent evolution and multiple outcomes. Mol Cancer Then 2004, 3(8):941-953.
130. Maglione J.E., Moghanaki D., Young L.J., Manner C.K., Ellies L.G., Joseph S.O., et al. Transgenic polyoma middle-T mice model pre-malignant mammary disease. Cancer Res. 2001, 61(22):8298-8305.
131. Mahler J.F., Stokes W, Mann P.C., Takaoka M., Maronpot R.R. Spontaneous lesions in aging FVB/N mice. Toxicol Pathol 1996, 24(6):710-716.
132. Majumder P.K., Yeh J.J., George D.J., Febbo P.G., Kum J., Xue Q., et al. Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc. Natl. Acad. Sci. USA 2003, 100:7841-7846. 13.
133. Man A.K., Young L.J., Tynan J.A., Lesperance J., Egeblad M., Werb Z., et al. Ets2-Dependent Stromal Regulation of Mouse Mammary Tumors. Mol. Cell Biol 2003, 23(23):8614-8625.
134. Pathology of the mouse: reference and atlas 1999, Cache River Press, Vienna IL. R.R. Maronpot, G.A. Boorman, B.W. Gaul (Eds.).
135. Martin G.R. Teratocarcinomas and mammalian embryogenesis. Science 1980, 209(4458):768-776.
136. Masumori N., Thomas T.Z., Chaurand P., Case T., Paul M., Kasper S., et al. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res. 2001, 61(5):2239-2249.
137. Matzinger S.A., Chen B., Wang Y, Crist K.A., Stoner G.D., Kelloff G.J., et al. Tissue-specific expression of the K-ras allele from the A/J parent in (A/J x TSG-p53) F1 mice. Gene 1997, 188(2):261-269.
138. McGrath C.M., Prass W.A., Maloney T.M., Jones R.F. Induction of endogenous mammary tumor virus expression during hormonal induction of mammary adenoacanthomas and carcinomas of BALB/c female mice. J. Natl. Cancer Inst. 1981, 67(4):841-852.
139. Medina D. The mammary gland: a unique organ for the study of devel-opment and tumorigenesis. J. Mammary Gland. Biol. Neoplasia 1996, 1(1):5-19.
140. Medina D. The preneoplastic phenotype in murine mammary tumori-genesis. J. Mammary Gland. Biol. Neoplasia 2000, 5(4):393-407.
141. Medina D., Kittrell F.S., Shepard A., Stephens L.C., Jiang C., Lu J., et al. Biological and genetic properties of the p53null preneoplastic mammary epithelium. Faseb. J. 2002, 16(8):881-883.
142. Meuwissen R., Linn S.C., Linnoila R.L, Zevenhoven J., Mooi W.J., Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rbl in a conditional mouse model. Cancer Cell 2003, 4(3):181-189.
143. Minna J.D., Kurie J.M., Jacks T. A big step in the study of small cell lung cancer. Cancer Cell 2003, 4(3):163-166.
144. Miyoshi K., Rosner A., Nozawa M., Byrd C., Morgan F., Landesman-Bollag E., et al. Activation of different Wnt/beta-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002, 21(36):5548-5556.
145. Miyoshi K., Shillingford J.M., Le Provost F, Gounari F, Bronson R., von Boehmer H., et al. Activation of beta-catenin signaling in differen-tiated mammary secretory cells induces transdifferentiation into epidermis and squamous metaplasias. Proc. Natl. Acad. Sci. USA 2002, 99:219-224. 1.
146. Pathobiology of the aging mouse 2 vols 1996, International Life Sciences Institute, Washington DC. U. Mohr, D.L. Dungworth, C.C. Capen, W.W. Carlton, J.P. Sundberg, J.M. Ward (Eds.).
147. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2002, 2(6):451-461.
148. Morris D.W, Bradshaw H.D., Billy H.T., Munn R.J., Cardiff R.D. Isolation of a pathogenic clone of mouse mammary tumor virus. J. Virol. 1989, 63(1):148-158.
149. Morse H.C., Anver M.R., Fredrickson T.N., Haines D.C., Harris A.W., Harris N.L., et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood 2002, 100(1):246-258.
150. Moser A.R., Hegge L.F., Cardiff R.D. Genetic background affects susceptibility to mammary hyperplasias and carcinomas in Apc (min) /+ mice. Cancer Res. 2001, 61(8):3480-3485.
151. Muller W.J., Sinn E., Pattengale P.K., Wallace R., Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988, 54(1):105-115.
152. Nagase H., Mao J.H., Balmain A. A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. Proc. Natl. Acad. Sci. USA 1999, 96:15032-15037. 26.
153. Naharro G., Tronick S.R., Rasheed S., Gardner M.B., Aaronson S.A., Robbins K.C. Molecular cloning of integrated Gardner-Rasheed feline sarcoma virus: genetic structure of its cell-derived sequence differs from that of other tyrosine kinase-coding onc genes. J. Virol. 1983, 47(3):611-619.
154. Namba R., Maglione J.E., Young L.J., Borowsky A.D., Cardiff R.D., MacLeod C.L., et al. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol. Cancer Res. 2004, 2(8):453-463.
155. Neznanov N., Man A.K., Yamamoto H., Hauser C.A., Cardiff R.D., Oshima R.G. A single targeted Ets2 allele restricts development of mammary tumors in transgenic mice. Cancer Res. 1999, 59(17):4242-4246.
156. Nicolson G.L. Paracrine and autocrine growth mechanisms in tumor metastasis to specific sites with particular emphasis on brain and lung metas-tasis. Cancer Metastasis Rev. 1993, 12(3-4):325-343.
157. Nieto A.I., Shyamala G., Galvez J.J., Cardiff R.D. Persistent hyperplasia in FVB/N. Comparative Medicine 2003, 53(4):361-366.
158. Nikitin A.Y, Alcaraz A., Anver M.R., Bronson R.T., Cardiff R.D., Dixon D., et al. Classification of proliferative pulmonary lesions of the mouse: recommendations of the mouse models of human cancers consortium. Cancer Res. 2004, 64(7):2307-2316.
159. Oshima R.G., Lesperance J., Munoz V., Hebbard L., Ranscht B., Sharan N., et al. Angiogenic acceleration of neu induced mammary tumor progression and metastasis. Cancer Res. 2004, 64(1):169-179.
160. Park J.H., Walls J.E., Galvez J.J., Kim M., Abate-Shen C., Shen M.M., et al. Prostatic intraepithelial neoplasia in genetically engineered mice. Am. J. Pathol. 2002, 161(2):727-735.
161. Parmigiani G., Garrett-Mayer E.S., Anbazhagan R., Gabrielson E. A cross-study comparison of gene expression studies for the molec-ular classification of lung cancer. Clin Cancer Res. 2004, 10(9):2922-2927.
162. Pattengale P.K., Stewart T.A., Leder A., Sinn E., Mu die;ller W, Tepler L, et al. Animal models of human disease. Pathology and molecular biology of spontaneous neoplasms occurring in transgenic mice carrying and expressing activated cellular oncogenes. Am. J. Pathol. 1989, 135(1):39-61.
163. Powell W.C., Cardiff R.D., Cohen M.B., Miller G.J., Roy-Burman P. Mouse strains for prostate tumorigenesis based on genes altered in human prostate cancer. Curr. Drug Targets 2003, 4(3):263-279.
164. Rosner A., Miyoshi K., Landesman-Bollag E., Xu X., Seldin D.C., Moser A.R., et al. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am. J. Pathol. 2002, 161(3):1087-1097.
165. Ross J.S., Schenkein D.P., Kashala O., Linette G.P., Stec J., Symmans W.F., et al. Pharmacogenomics. Adv. Anat. Pathol. 2004, 11(4):211-220.
166. Ross M.E., Zhou X., Song G., Shurtleff S.A., Girtman K., Williams W.K., et al. Classification of pediatrie acute lymphoblastic leukemia by gene expression profiling. Blood 2003, 102(8):2951-2959.
167. Rosse C., Mejino J.L.Jr. A reference ontology for biomedical infor-matics: the foundational model of anatomy. J. Biomed. Inform. 2003, 36(6):478-500.
168. Saenz Robles M.T., Symonds H., Chen J., Van Dyke T. Induction versus progression of brain tumor development: differential functions for the pRB-and p53-targeting domains of simian virus 40 T antigen. Mol Cell Biol 1994, 14(4):2686-2698.
169. Saez E., Rosenfeld J., Livolsi A., Olson P., Lombardo E., Nelson M., et al. PPAR(gamma) signaling exacerbates mammary gland tumor devel-opment. Genes Dev. 2004, 18(5):528-540.
170. Sandgren E.P., Schroeder J.A., Qui T.H., Palmiter R.D., Brinster R.L., Lee D.C. Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res. 1995, 55(17):3915-3927.
171. Sass B., Dunn T.B. Classification of mouse mammary tumors in Dunn's miscellaneous group including recently reported types. J. Natl. Cancer Inst. 1979, 62(5):1287-1293.
172. Scherl A., Li J.F., Cardiff R.D., Schreiber-Agus N. Prostatic intraepithelial neoplasia and intestinal metaplasia in prostates of probasin-RAS transgenic mice. Prostate 2004, 59(4):448-459.
173. Schmidt E.V. The role of c-myc in cellular growth control. Oncogene 1999, 18(19):2988-2996.
174. Schmidt E.V. The role of c-myc in regulation of translation initiation. Oncogene 2004, 23(18):3217-3221.
175. Schoenenberger C.A., Andres A.C., Groner B., van der Valk M., LeMeur M., Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumours with constitutive milk protein gene transcription. Embo J. 1988, 7(1):169-175.
176. Shachaf C.M., Kopelman A.M., Arvanitis C., Karlsson A., Beer S., Mandl S., et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004.
177. Shappell S.B., Thomas G.V., Roberts R.L., Herbert R., Ittmann M.M., Rubin M.A., et al. Prostate pathology of genetically engineered mice: definitions and classification. The consensus report from the Bar Harbor meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee. Cancer Res. 2004, 64(6):2270-2305.
178. Sheiness D., Bishop J.M. DNA and RNA from uninfected verte-brate cells contain nucleotide sequences related to the putative transforming gene of avian myelocytomatosis virus. J. Virol. 1979, 31(2):514-521.
179. Sheiness D.K., Hughes S.H., Varmus H.E., Stubblefield E., Bishop J.M. The vertebrate homolog of the putative transforming gene of avian myelocytomatosis virus: characteristics of the DNA locus and its RNA transcript. Virology 1980, 105(2):415-424.
180. Shubik P. Progression and promotion. J. Natl. Cancer Inst. 1984, 73(5):1005-1011.
181. Siegel P.M., Shu W., Cardiff R.D., Muller W.J., Massague J. Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc. Natl. Acad. Sci. USA 2003, 100:8430-8435. 14.
182. Sinn E., Muller W., Pattengale P., Tepler I., Wallace R., Leder P. Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 1987, 49(4):465-475.
183. Snyder S.P., Theilen G.H. Transmissible feline fibrosarcoma. Nature 1969, 221(185):1074-1075.
184. Song Z., Wu X., Powell W.C., Cardiff R.D., Cohen M.B., Tin R.T., et al. Fibroblast growth factor 8 isoform B overexpression in prostate epithelium: a new mouse model for prostatic intraepithelial neoplasia. Cancer Res. 2002, 62(17):5096-5105.
185. Sorlie T. Molecular portraits of breast cancer: tumour subtypes as dis-tinct disease entities. Eur. J. Cancer 2004, 40(18):2667-2675.
186. Sternlicht M.D., Lochter A., Sympson C.J., Huey B., Rougier J.P., Gray J.W, et al. The stromal proteinase MMP3/stromelysin-l promotes mam-mary carcinogenesis. Cell 1999, 98(2):137-146.
187. Stevens L.C. Teratocarcinogenesis and spontaneous parthenogenesis in mice. Results Probl. Cell. Differ. 1980, 11:265-274.
188. Strange R., Aguilar-Cordova E., Young L.J., Billy H.T., Dandekar S., Cardiff R.D. Harvey-ras mediated neoplastic development in the mouse mammary gland. Oncogene 1989, 4(3):309-315.
189. Sugino T., Kusakabe T., Hoshi N., Yamaguchi T., Kawaguchi T., Goodison S., et al. An invasion-independent pathway of blood-borne metastasis: a new murine mammary tumor model. Am. J. Pathol. 2002, 160(6):1973-1980.
190. Taub R., Kirsch I., Morton C., Lenoir G., Swan D., Tronick S., et al. Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc. Natl. Acad. Sci. USA 1982, 79:7837-7841. 24.
191. Tehranian A., Morris D.W., Min B.H., Bird D.J., Cardiff R.D., Barry P.A. Neoplastic transformation of prostatic and urogenital epithelium by the polyoma virus middle T gene. Am. J. Pathol. 1996, 149(4):1177-1191.
192. Teitelman G., Alpert S., Hanahan D. Proliferation senescence and neoplastic progression of beta cells in hyperplasic pancreatic islets. Cell 1988, 52(1):97-105.
193. Tulchin N., Lee F.S., Ornstein L., Strauchen J., Cardiff R.D. c-myc protein distribution: Mammary adenocarcinomas of MTV/MYC transgenic mice. Interntl. J. Oncology. 1995, 7:5-9.
194. Urashima M., Chen B.P., Chen S., Pinkus G.S., Bronson R.T., Dedera D.A., et al. The development of a model for the homing of multiple myeloma cells to human bone marrow. Blood 1997, 90(2):754-765.
195. Vaage J. A survey of in vivo growth characteristics and spontaneous metastasizing potentials of C3H mouse mammary tumors. Int. J. Cancer 1989, 43(5):910-914.
196. van Leeuwen F., Nusse R. Oncogene activation and oncogene cooperation in MMTV-induced mouse mammary cancer. Semin. Cancer Biol. 1995, 6(3):127-133.
197. Vennstrom B., Sheiness D., Zabielski J., Bishop J.M. Isolation and characterization of c-myc a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J. Virol. 1982, 42(3):773-779.
198. Verma I.M., Graham W.R. The fos oncogene. Adv. Cancer Res. 1987, 49:29-52.
199. Vogelstein B., Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 2004, 10(8):789-799.
200. Wakefield L.M., Thordarson G., Anver M., Cardiff R.D. Spontaneous pituitary abnormalities and mammary hyperplasias in FVB/NCr mice: implications for mouse modeling. Comp. Med. 2003, 53(4):348-356.
201. Wang Y, Hayward S.W., Donjacour A.A., Young P., Jacks T., Sage J., et al. Sex hormone-induced carcinogenesis in Rb-deficient prostate tissue. Cancer Res 2000, 60(21):6008-6017.
202. Warner J.K., Wang J.C., Hope K.J., Jin L., Dick J.E. Concepts of human leukemic development. Oncogene 2004, 23(43):7164-7177.
203. Webster M.A., Hutchinson J.N., Rauh M.J., Muthuswamy S.K., Anton M., Tortorice C.G., et al. Requirement for both Shc and phosphatidyli-nositol 3 prime; kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol. Cell. Biol. 1998, 18(4):2344-2359.
204. Weinstein R.S., Bloom K.J., Rozek L.S. Telepathology. Long-distance diagnosis. Am. J. Clin. Pathol. 1989, 91(4):S39-S42. Suppl 1.
205. Weiss W.A., Israel M., Cobbs C., Holland E., James C.D., Louis D.N., et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002, 21(49):7453-7463.
206. Wen F., Cecena G., Munoz-Ritchie V., Fuchs E., Chambon P., Oshima R.G. Expression of conditional Cre recombinase in epithelial tissues of transgenic mice. Genesis 2003, 35(2):100-106.
207. White D.E., Cardiff R.D., Dedhar S., Muller W.J. Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice. Oncogene 2001, 20(48):7064-7072.
208. White D.E., Kurpios N.A., Zuo D., Hassell J.A., Blaess S., Mueller U., et al. Targeted disruption of betal-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell 2004, 6(2):159-170.
209. Yew N., Strobel M., Vande Woude G.F Mos and the cell cycle: the molecular basis of the transformed phenotype. Curr. Opin. Genet. Dev. 1993, 3(1):19-25.
210. Yoshidome K., Shibata M.A., Maroulakou I.G., Liu M.L., Jorcyk C.L., Gold L.G., et al. Genetic alterations in the development of mammary and prostate cancer in the C3 (l) /Tag transgenic mouse model. Int. J. Oncol 1998, 12(2):449-453.
211. Yu Q., Geng Y, Sicinski P. Specific protection against breast cancers by cyclin Dl ablation. Nature 2001, 411(6841):1017-1021.